A double-blind placebo-controlled trial of the effect of perindopril on muscle strength and functional capacity in older people

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN67679521

Enrollment

148

Registered

2005-03-31

Start date

2003-08-06

Completion date

Unknown

Last updated

2018-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sarcopenia Musculoskeletal Diseases Sarcopenia and loss of muscle strength and function

Interventions

Perindopril or placebo given for a period of 20 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Older people over the age of 65 years with some dependence in activities of daily living

Exclusion criteria

Exclusion criteria: 1. Without left ventricular systolic dysfunction 2. Already receiving an angiotensin converting enzyme (ACE) inhibitor or an angiotensin II inhibitor 3. Contraindication to ACE inhibitors 4. Unable to give informed consent

Design outcomes

Primary

Measure	Time frame
Change in the 6-minute walking distance over the 20 weeks	—

Secondary

Measure	Time frame
1. Changes in muscle function 2. Daily activity levels 3. Self-reported function 4. Health-related quality of life	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Apr 6, 2026